Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study

Figures

• 

  Figure 1. Patient selection flow chart. DVT/PE deep vein thrombosis/pulmonary embolism; HIV human immunodeficiency virus; NVAF non-valvular atrial fibrillation, OAC oral anticoagulant, NOAC Non-vitamin K antagonist oral anticoagulant; VKA vitamin K antagonist.

• 

  Figure 2. Subgroup and sensitivity analyses: Hazard ratios of acute liver injury for each type of NOAC, compared to VKA, in patients with no prior liver disease (main study population). (A) Hospitalized acute liver injury. (B) Elevation of transaminases (proxy, ancillary outcome). *Main analysis: hazard ratio adjusted by using inverse probability treatment weighting with truncation at the 0.1th and 99.9th percentiles (unlike with trimming, no patients excluded). †Standard doses: dabigatran 150 mg, rivaroxaban 20 mg and apixaban 5 mg; Reduced doses: dabigatran 110 or 75 mg, rivaroxaban 15 or 10 mg and apixaban 2.5 mg. ‡See the list in Supplementary Table 3. §See definition of frailty in Supplementary Table 2. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ ^{\P} $$\end{document}¶During the influenza vaccination campaign directly preceding the index date. Further adjustment on history of chronic alcoholism, see definition in Supplementary Table 2. **Asymmetric PS trimming: compared to the main analysis, 82.5% (N…